All In Biotech

Drug Trial Radar · NCT07688577

XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX501 in Participants With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Oct 21, 2026

Primary completion

Nov 2029

Study completion Nov 2029

Sponsor

Lead sponsor
Xilio Development, Inc.Industry
Sponsor type
Industry
First posted
Jul 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX501 as monotherapy in participants with metastatic non-small cell lung cancer (NSCLC) and select advanced solid tumors.

Conditions

  • Metastatic NSCLC - Non-Small Cell Lung Cancer
  • Advanced Solid Tumor

Interventions

  • XTX501Drug

    XTX501 monotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs) in Part 1ATime frame: Cycle 1 Day 1 up to just prior to the second dose of study drug (approximately 21 days)
  2. Incidence of treatment-emergent adverse events (Phase 1 and Phase 2)Time frame: Up to Safety Follow Up Period (90 [+7] days after the last dose)
  3. Incidence of serious adverse events (Phase 1 and Phase 2)Time frame: Up to Safety Follow Up Period (90 [+7] days after the last dose)
  4. Incidence of significant change from baseline in clinical laboratory values (Phase 1 and Phase 2)Time frame: Up to Safety Follow Up Period (90 [+7] days after the last dose)
  5. Investigator-assessed objective response rate (ORR) per RECIST v1.1 (Phase 2)Time frame: Up to Safety Follow Up Period (90 [+7] days after the last dose)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Investigator Site

    Canton, Ohio · Recruiting

  • Investigator Site

    Fort Worth, Texas · Recruiting

  • Investigator Site

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.